Lophius seals successful round of finance
Lophius Biosciences GmbH, a biotechnology company founded from the Regensburg University Clinic, is a leading developer of novel T-cell based diagnostic test systems. T-cells belong to the cell groups of lymphocytes and play an important role in the human immune system. The company develops and markets innovative test systems for the diagnosis and possible direction of treatment in the fields of transplantation, infectious disease and autoimmune disease. In the current press release the company announced the successful sealing of a further round of finance. With VRD GmbH and WIC GmbH two other new investors have participated in Lophius Biosciences within the framework of this financial round – in addition to the existing finance investors S-Refit, HighTech Gründerfonds (HTGF), Bayern Kapital and two business angels from the shareholder group. VRD GmbH belongs to the family business of an entrepreneurial family steeped in tradition with its headquarters in Heidelberg. WIC GmbH is a young investment and consultancy company. Finance of round 4 million € was agreed upon, which aims to place developed technology and products from Lophius Biosciences in the field of T-cell diagnostic successfully on the market. Furthermore Prof. Dr. Ralf Wagner, former chairman of the board of Regensburg GeneArt AG, is to enter the management of the company, to work together with the official CEO Dr. Michael Lutz to push forward further development of the company.
For more information see: